Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 1
1975 1
1977 2
1978 1
1979 1
1980 1
1981 1
1982 2
1983 6
1984 1
1985 1
1986 5
1987 6
1988 8
1989 11
1990 11
1991 21
1992 20
1993 21
1994 20
1995 31
1996 41
1997 38
1998 60
1999 77
2000 107
2001 104
2002 108
2003 129
2004 163
2005 188
2006 226
2007 284
2008 325
2009 366
2010 428
2011 496
2012 563
2013 586
2014 636
2015 702
2016 638
2017 717
2018 706
2019 718
2020 785
2021 837
2022 743
2023 762
2024 193

Text availability

Article attribute

Article type

Publication date

Search Results

10,559 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. Among authors: park sh. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. Among authors: park sh. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Van der Waals Colloidal Crystals.
Cho Y, Park SH, Kwon M, Kim HH, Huh JH, Lee S. Cho Y, et al. Among authors: park sh. Adv Mater. 2024 Mar 7:e2312748. doi: 10.1002/adma.202312748. Online ahead of print. Adv Mater. 2024. PMID: 38450572 Catalan.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Among authors: park sh. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Brain Tumor Classification by Methylation Profile.
Park JW, Lee K, Kim EE, Kim SI, Park SH. Park JW, et al. Among authors: park sh. J Korean Med Sci. 2023 Nov 6;38(43):e356. doi: 10.3346/jkms.2023.38.e356. J Korean Med Sci. 2023. PMID: 37935168 Free PMC article. Review.
IL-15 in T-Cell Responses and Immunopathogenesis.
Lee H, Park SH, Shin EC. Lee H, et al. Among authors: park sh. Immune Netw. 2024 Feb 16;24(1):e11. doi: 10.4110/in.2024.24.e11. eCollection 2024 Feb. Immune Netw. 2024. PMID: 38455459 Free PMC article. Review.
10,559 results
You have reached the last available page of results. Please see the User Guide for more information.